GeneDx Holdings Corp. (WGS) Securities Fraud Investigation - Levi & Korsinsky

GeneDx posted Q1 2026 revenue of $102.3 million against consensus estimates near $110 million and reported adjusted EPS of -$0.28 versus the -$0.01 expected -- the stock collapsed approximately 44% in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Shareholders who held GeneDx Holdings Corp. (NASDAQ: WGS) stock lost approximately 44% of their investment value when the company reported Q1 2026 results that fell sharply below Wall Street expectations.